Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy

被引：0
|
作者：
Desai, Milind Y. [1 ]
Ali, Adel Hajj [1 ]
机构：
[1] Cleveland Clin, Heart Vasc Thorac Inst, Hypertroph Cardiomyopathy Ctr, Cleveland, OH 44106 USA
来源：
HEART INTERNATIONAL | 2023年 / 17卷 / 01期
关键词：
Cardiac myosin inhibitor; cardiology; cardiovascular diseases; hypertrophic cardiomyopathy; mavacamten; septal reduction therapy; DOUBLE-BLIND; ADULTS; HCM;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.
引用
收藏
页码：2 / 4
页数：3
相关论文
共 50 条
  • [31] Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1652): : 89 - 91
  • [32] Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review
    Aguiar, Tiago
    Martins, Elisabete
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2022, 41 (08) : 693 - 703
  • [33] eComment. Septal reduction therapy for hypertrophic cardiomyopathy: the need of experienced centres
    Garcia-Villarreal, Ovidio A.
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2013, 16 (01) : 9 - 10
  • [34] Contemporary Septal Reduction Therapy in Drug-Refractory Hypertrophic Obstructive Cardiomyopathy
    Maekawa, Yuichiro
    Akita, Keitaro
    Takanashi, Shuichiro
    CIRCULATION JOURNAL, 2018, 82 (08) : 1977 - 1984
  • [35] COSTS OF SEPTAL REDUCTION THERAPY FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A US CLAIMS ANALYSIS
    Butzner, M.
    Sarocco, P.
    Maron, M.
    Rowin, E.
    Teng, C. C.
    Stanek, E.
    Tan, H.
    Robertson, L.
    VALUE IN HEALTH, 2021, 24 : S73 - S73
  • [36] IMPACT OF PULMONARY HYPERTENSION ON SEPTAL REDUCTION THERAPY OUTCOMES FOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
    Isath, Ameesh
    Lanier, Gregg M.
    Spielvogel, David
    Malekan, Ramin
    Steinmetz, Carolyn
    Semaan, Rosa
    Fishkin, Tzvi
    Panza, Julio A.
    Naidu, Srihari S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 549 - 549
  • [37] Interventional septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy- a relief also for the right ventricle?
    Sosdean, R.
    Mircea, M.
    Pascalau, L.
    Pescariu, S. A.
    Cristescu, R.
    Sturza, A.
    Luca, C. T.
    Mornos, C.
    Ionac, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 380 - 380
  • [38] Predictors of outcome after non-surgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy
    Chang, SM
    Lakkis, NM
    Spencer, WH
    Nagueh, SF
    CIRCULATION, 2003, 108 (17) : 492 - 493
  • [39] Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy
    Bataiosu, D.
    Lee, D. Z. J.
    Montazeri, M.
    Billia, F.
    Ralph-Edwards, T.
    Rakowski, H.
    Chan, R.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [40] Three-Dimensional Heart Printing for Planning of Septal Reduction Therapy in Patients with Hypertrophic Obstructive Cardiomyopathy
    Veselka, Josef
    Adla, Theodor
    Adlova, Radka
    Bartel, Thomas
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2018, 27 (03) : 165 - 166
12345